Open-Angle Glaucoma / Ocular Hypertension

Athena Study

About The Study:

Principal Investigator: Bruce E. Prum, Jr., MD

Sponsored by Allergan, the purpose of this multi-center study is to investigate the safety and effectiveness of Bimatoprost SR compared with selective laser trabeculoplasty (SLT) in glaucoma or ocular hypertension.

All participants will be randomized to one of two study groups:

Group A—SLT in the primary eye and Bimatoprost SR in the fellow eye
Group B—Bimatoprost SR in the primary eye and SLT in the fellow eye

Participants participating in this study will make up to 22 scheduled study visits and 7 phone calls over a period of 14 months. Each visit will last anywhere from 2-5 hours.

Key Inclusion Criteria:

Age ≥ 18 years
IOP not adequately managed with topical medication for reasons other than medication efficacy—due to intolerance or nonadherence
IOP ≥ 22 and ≤ 34 mmHg
BCVA of 20/50 or better in the study eye

Key Exclusion Criteria:

History of previous laser trabeculoplasty
History of traumatic cataract and/or angle recession
Central corneal thickness of < 480 or > 620 micrometers
History of peripheral iridotomy/iridectomy in the inferior 180° of the iris
Any history of trabeculectomy or other types of glaucoma surgery
History of moderate or worse (≥2+) bulbar conjunctival hyperermia due to prostaglandin, prostamide, or prostaglandin use

For additional information about the trials or to refer a patient, contact the study coordinators:

Ashton Leone, MPH at (434) 243-5737 or aml7q@virginia.edu
Tamika Mercer at (434) 243-2852 or tmm2v@virginia.edu